FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1904077575> ?p ?o ?g. }

• W1904077575 abstract "Background Eighty to 90% of children with steroid‐sensitive nephrotic syndrome (SSNS) have relapses. About half relapse frequently and are at risk of the adverse effects of corticosteroids. Non‐corticosteroid immunosuppressive agents are used to prolong periods of remission in these children, however these agents have significant potential adverse effects. Currently there is no consensus as to the most appropriate second line agent in children who are steroid sensitive, but who continue to relapse. Objectives To evaluate the benefits and harms of non‐corticosteroid immunosuppressive agents in relapsing SSNS in children. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, reference lists, conference abstracts and contact with known investigators. Selection criteria Randomised controlled trials (RCTs) or quasi‐RCTs were included if they compared non‐corticosteroid agents with placebo, prednisone or no treatment, different doses and/or durations of the same non‐corticosteroid agent, different non‐corticosteroid agents. Data collection and analysis Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI). Main results We identified 26 studies (1173 children). Cyclophosphamide (RR 0.44, 95% CI 0.26 to 0.73) and chlorambucil (RR 0.15, 95% CI 0.02 to 0.95) significantly reduced the relapse risk at six to twelve months compared with prednisone alone. There was no difference in relapse risk at two years between chlorambucil and cyclophosphamide (RR 1.31, 95% CI 0.80 to 2.13). There was no difference at one year between intravenous and oral cyclophosphamide (RR 0.99, 95% CI 0.76 to 1.29). Cyclosporin was as effective as cyclophosphamide (RR 1.07, 95% CI 0.48 to 2.35) and chlorambucil (RR 0.82, 95% CI 0.44 to 1.53) and levamisole (RR 0.43, 95% CI 0.27 to 0.68) was more effective than steroids alone but the effects were not sustained once treatment was stopped. There was no difference in the risk for relapse between mycophenolate mofetil and cyclosporin (RR 5.00, 95% CI 0.68 to 36.66) but CI were large. Mizoribine and azathioprine were no more effective than placebo or prednisone alone in maintaining remission. Authors' conclusions Eight week courses of cyclophosphamide or chlorambucil and prolonged courses of cyclosporin and levamisole reduce the risk of relapse in children with relapsing SSNS compared with corticosteroids alone. Clinically important differences in efficacy are possible and further comparative studies are still needed." @default.
• W1904077575 created "2016-06-24" @default.
• W1904077575 creator A5020634465 @default.
• W1904077575 creator A5038938109 @default.
• W1904077575 creator A5051609819 @default.
• W1904077575 creator A5056074771 @default.
• W1904077575 date "2008-01-23" @default.
• W1904077575 modified "2023-09-25" @default.
• W1904077575 title "Non-corticosteroid treatment for nephrotic syndrome in children" @default.
• W1904077575 cites W1491720051 @default.
• W1904077575 cites W1967091682 @default.
• W1904077575 cites W1967181593 @default.
• W1904077575 cites W1968348071 @default.
• W1904077575 cites W1969400644 @default.
• W1904077575 cites W1971311178 @default.
• W1904077575 cites W1972310654 @default.
• W1904077575 cites W1977392594 @default.
• W1904077575 cites W1980517783 @default.
• W1904077575 cites W1980836240 @default.
• W1904077575 cites W1993484566 @default.
• W1904077575 cites W1996339513 @default.
• W1904077575 cites W1996563886 @default.
• W1904077575 cites W1998220895 @default.
• W1904077575 cites W2005367998 @default.
• W1904077575 cites W2007689247 @default.
• W1904077575 cites W2016524458 @default.
• W1904077575 cites W2021397728 @default.
• W1904077575 cites W2021616554 @default.
• W1904077575 cites W2024658711 @default.
• W1904077575 cites W2031954310 @default.
• W1904077575 cites W2035851258 @default.
• W1904077575 cites W2035947097 @default.
• W1904077575 cites W2038372397 @default.
• W1904077575 cites W2039610743 @default.
• W1904077575 cites W2039902077 @default.
• W1904077575 cites W2040766157 @default.
• W1904077575 cites W2052984045 @default.
• W1904077575 cites W2054404003 @default.
• W1904077575 cites W2057806510 @default.
• W1904077575 cites W2060618888 @default.
• W1904077575 cites W2069649947 @default.
• W1904077575 cites W2076378345 @default.
• W1904077575 cites W2083829458 @default.
• W1904077575 cites W2086455046 @default.
• W1904077575 cites W2088382294 @default.
• W1904077575 cites W2093256168 @default.
• W1904077575 cites W2093288851 @default.
• W1904077575 cites W2094025446 @default.
• W1904077575 cites W2101944817 @default.
• W1904077575 cites W2112214430 @default.
• W1904077575 cites W2113984710 @default.
• W1904077575 cites W2115161561 @default.
• W1904077575 cites W2122941588 @default.
• W1904077575 cites W2125435699 @default.
• W1904077575 cites W2128438977 @default.
• W1904077575 cites W2134338262 @default.
• W1904077575 cites W2134425923 @default.
• W1904077575 cites W2134772591 @default.
• W1904077575 cites W2135333084 @default.
• W1904077575 cites W2145810533 @default.
• W1904077575 cites W2171035768 @default.
• W1904077575 cites W2301544544 @default.
• W1904077575 cites W2324327113 @default.
• W1904077575 cites W2336670394 @default.
• W1904077575 cites W2337791726 @default.
• W1904077575 cites W4214559180 @default.
• W1904077575 cites W4233566643 @default.
• W1904077575 cites W4238630369 @default.
• W1904077575 cites W4247480917 @default.
• W1904077575 cites W4251694231 @default.
• W1904077575 cites W4254188701 @default.
• W1904077575 doi "https://doi.org/10.1002/14651858.cd002290.pub3" @default.
• W1904077575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18254005" @default.
• W1904077575 hasPublicationYear "2008" @default.
• W1904077575 type Work @default.
• W1904077575 sameAs 1904077575 @default.
• W1904077575 citedByCount "74" @default.
• W1904077575 countsByYear W19040775752012 @default.
• W1904077575 countsByYear W19040775752013 @default.
• W1904077575 countsByYear W19040775752014 @default.
• W1904077575 countsByYear W19040775752015 @default.
• W1904077575 countsByYear W19040775752016 @default.
• W1904077575 countsByYear W19040775752017 @default.
• W1904077575 countsByYear W19040775752018 @default.
• W1904077575 countsByYear W19040775752019 @default.
• W1904077575 countsByYear W19040775752020 @default.
• W1904077575 countsByYear W19040775752021 @default.
• W1904077575 crossrefType "reference-entry" @default.
• W1904077575 hasAuthorship W1904077575A5020634465 @default.
• W1904077575 hasAuthorship W1904077575A5038938109 @default.
• W1904077575 hasAuthorship W1904077575A5051609819 @default.
• W1904077575 hasAuthorship W1904077575A5056074771 @default.
• W1904077575 hasConcept C126322002 @default.
• W1904077575 hasConcept C142724271 @default.
• W1904077575 hasConcept C168563851 @default.
• W1904077575 hasConcept C187212893 @default.
• W1904077575 hasConcept C197934379 @default.
• W1904077575 hasConcept C204787440 @default.
• W1904077575 hasConcept C27081682 @default.
• W1904077575 hasConcept C2776694085 @default.

• next